Cargando…

Pharmacokinetic Evaluation of [(11)C]CEP-32496 in Nude Mice Bearing BRAF(V600E) Mutation-Induced Melanomas

CEP-32496, also known as RXDX-105 or Agerafenib, is a new orally active inhibitor for the mutated v-raf murine sarcoma viral oncogene homolog B1 (BRAF(V600E)), which has attracted considerable attention in clinical trials for the treatment of human cancers. Here, we used carbon-11-labeled CEP-32496...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Cuiping, Xie, Lin, Zhang, Yiding, Fujinaga, Masayuki, Mori, Wakana, Kurihara, Yusuke, Yamasaki, Tomoteru, Wang, Feng, Zhang, Ming-Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156206/ https://www.ncbi.nlm.nih.gov/pubmed/30251592 http://dx.doi.org/10.1177/1536012118795952

Ejemplares similares

Automated radiosynthesis and in vivo evaluation of (18)F-labeled analog of the photosensitizer ADPM06 for planning photodynamic therapy
por: Kawamura, Kazunori, et al.
Publicado: (2023)

In Vivo Monitoring for Regional Changes of Metabotropic Glutamate Receptor Subtype 1 (mGluR1) in Pilocarpine-Induced Epileptic Rat Brain by Small-Animal PET
por: Yamasaki, Tomoteru, et al.
Publicado: (2017)

Radiosynthesis and in vivo evaluation of (11)C-labeled BMS-193885 and its desmethyl analog as PET tracers for neuropeptide Y1 receptors
por: Kawamura, Kazunori, et al.
Publicado: (2019)

Neuroprotective effects of minocycline and KML29, a potent inhibitor of monoacylglycerol lipase, in an experimental stroke model: a small-animal positron emission tomography study
por: Yamasaki, Tomoteru, et al.
Publicado: (2021)

Development of 1-N-(11)C-Methyl-l- and -d-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan
por: Xie, Lin, et al.
Publicado: (2015)

Synthesis of [(11)C]carbonyl-labeled cyclohexyl (5-(2-acetamidobenzo[d]thiazol-6-yl)-2-methylpyridin-3-yl)carbamate ([(11)C-carbonyl]PK68) as a potential PET tracer for receptor-interacting protein 1 kinase
por: Yamasaki, Tomoteru, et al.
Publicado: (2022)

Pharmacokinetic Approach to Rational Therapeutic Doses for Human Tumor‐bearing Nude Mice
por: Inaba, Makoto, et al.
Publicado: (1988)

Development of Novel (11)C-Labeled Selective Orexin-2 Receptor Radioligands for Positron Emission Tomography Imaging
por: Rong, Jian, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Synthesis and Preclinical Evaluation of Sulfonamido-based [(11)C-Carbonyl]-Carbamates and Ureas for Imaging Monoacylglycerol Lipase
por: Wang, Lu, et al.
Publicado: (2016)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Virtual screening, pharmacokinetic, and DFT studies of anticancer compounds as potential V600E-BRAF kinaseinhibitors
por: Umar, Abdullahi B., et al.
Publicado: (2023)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Automated radiosynthesis of two (18)F-labeled tracers containing 3-fluoro-2-hydroxypropyl moiety, [(18)F]FMISO and [(18)F]PM-PBB3, via [(18)F]epifluorohydrin
por: Ohkubo, Takayuki, et al.
Publicado: (2021)

BRAF V600E-mutated combined large cell neuroendocrine carcinoma and adenocarcinoma responding to targeted therapy
por: Sakamoto, Tomohiro, et al.
Publicado: (2021)

A Unique Case of Intracranial Amelanotic Melanoma with BRAF V600E Mutation Successfully Treated via Molecular-targeted Therapy
por: FUJITA, Juntaro, et al.
Publicado: (2023)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

Development of a highly-specific (18)F-labeled irreversible positron emission tomography tracer for monoacylglycerol lipase mapping
por: Chen, Zhen, et al.
Publicado: (2021)

New flavone-based arylamides as potential V600E-BRAF inhibitors: Molecular docking, DFT, and pharmacokinetic properties
por: Umar, Abdullahi B., et al.
Publicado: (2023)

[(18)F]FEBMP: Positron Emission Tomography Imaging of TSPO in a Model of Neuroinflammation in Rats, and in vitro Autoradiograms of the Human Brain
por: Tiwari, Anjani K., et al.
Publicado: (2015)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

BRAF V600E-Negative Hairy Cell Leukaemia
por: Langabeer, Stephen E., et al.
Publicado: (2013)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ac4di7vbf6s3vi7ro2lhee7toj